BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Prentoe J, Bukh J. Hypervariable Region 1 in Envelope Protein 2 of Hepatitis C Virus: A Linchpin in Neutralizing Antibody Evasion and Viral Entry. Front Immunol 2018;9:2146. [PMID: 30319614 DOI: 10.3389/fimmu.2018.02146] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 7.5] [Reference Citation Analysis]
Number Citing Articles
1 Gömer A, Delarocque J, Puff C, Nocke MK, Reinecke B, Baumgärtner W, Cavalleri JMV, Feige K, Steinmann E, Todt D. Dose-Dependent Hepacivirus Infection Reveals Linkage between Infectious Dose and Immune Response. Microbiol Spectr 2022;:e0168622. [PMID: 35993785 DOI: 10.1128/spectrum.01686-22] [Reference Citation Analysis]
2 Wang R, Suzuki S, Guest JD, Heller B, Almeda M, Andrianov AK, Marin A, Mariuzza RA, Keck ZY, Foung SKH, Yunus AS, Pierce BG, Toth EA, Ploss A, Fuerst TR. Induction of broadly neutralizing antibodies using a secreted form of the hepatitis C virus E1E2 heterodimer as a vaccine candidate. Proc Natl Acad Sci U S A 2022;119:e2112008119. [PMID: 35263223 DOI: 10.1073/pnas.2112008119] [Reference Citation Analysis]
3 Bankwitz D, Krey T, Pietschmann T. [Development approaches for vaccines against hepatitis C virus infections]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2022. [PMID: 35015104 DOI: 10.1007/s00103-021-03477-9] [Reference Citation Analysis]
4 Pihl AF, Feng S, Offersgaard A, Alzua GP, Augestad EH, Mathiesen CK, Jensen TB, Krarup H, Law M, Prentoe J, Christensen JP, Bukh J, Gottwein JM. Inactivated whole hepatitis C virus vaccine employing a licensed adjuvant elicits cross-genotype neutralizing antibodies in mice. J Hepatol 2022:S0168-8278(21)02303-5. [PMID: 34990750 DOI: 10.1016/j.jhep.2021.12.026] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
5 Tomlinson JE, Wolfisberg R, Fahnøe U, Patel RS, Trivedi S, Kumar A, Sharma H, Nielsen L, McDonough SP, Bukh J, Tennant BC, Kapoor A, Rosenberg BR, Rice CM, Divers TJ, Van de Walle GR, Scheel TKH. Pathogenesis, MicroRNA-122 Gene-Regulation, and Protective Immune Responses After Acute Equine Hepacivirus Infection. Hepatology 2021;74:1148-63. [PMID: 33713356 DOI: 10.1002/hep.31802] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
6 Augestad EH, Bukh J, Prentoe J. Hepatitis C virus envelope protein dynamics and the link to hypervariable region 1. Curr Opin Virol 2021;50:69-75. [PMID: 34403905 DOI: 10.1016/j.coviro.2021.07.006] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
7 Prentoe J, Janitzek CM, Velázquez-Moctezuma R, Goksøyr L, Olsen RW, Fanalista M, Augestad EH, Thrane S, Pihl AF, Gottwein JM, Sander AF, Bukh J. Antigenic and immunogenic evaluation of permutations of soluble hepatitis C virus envelope protein E2 and E1 antigens. PLoS One 2021;16:e0255336. [PMID: 34329365 DOI: 10.1371/journal.pone.0255336] [Reference Citation Analysis]
8 Olesen CH, Augestad EH, Troise F, Bukh J, Prentoe J. In vitro adaptation and characterization of attenuated hypervariable region 1 swap chimeras of hepatitis C virus. PLoS Pathog 2021;17:e1009720. [PMID: 34280245 DOI: 10.1371/journal.ppat.1009720] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Sevvana M, Keck Z, Foung SK, Kuhn RJ. Structural perspectives on HCV humoral immune evasion mechanisms. Curr Opin Virol 2021;49:92-101. [PMID: 34091143 DOI: 10.1016/j.coviro.2021.05.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
10 LeBlanc EV, Kim Y, Capicciotti CJ, Colpitts CC. Hepatitis C Virus Glycan-Dependent Interactions and the Potential for Novel Preventative Strategies. Pathogens 2021;10:685. [PMID: 34205894 DOI: 10.3390/pathogens10060685] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
11 Guest JD, Wang R, Elkholy KH, Chagas A, Chao KL, Cleveland TE 4th, Kim YC, Keck ZY, Marin A, Yunus AS, Mariuzza RA, Andrianov AK, Toth EA, Foung SKH, Pierce BG, Fuerst TR. Design of a native-like secreted form of the hepatitis C virus E1E2 heterodimer. Proc Natl Acad Sci U S A 2021;118:e2015149118. [PMID: 33431677 DOI: 10.1073/pnas.2015149118] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
12 Guest JD, Pierce BG. Structure-Based and Rational Design of a Hepatitis C Virus Vaccine. Viruses 2021;13:837. [PMID: 34063143 DOI: 10.3390/v13050837] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
13 Yechezkel I, Law M, Tzarum N. From Structural Studies to HCV Vaccine Design. Viruses 2021;13:833. [PMID: 34064532 DOI: 10.3390/v13050833] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Schlotthauer F, McGregor J, Drummer HE. To Include or Occlude: Rational Engineering of HCV Vaccines for Humoral Immunity. Viruses 2021;13:805. [PMID: 33946211 DOI: 10.3390/v13050805] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Velázquez-Moctezuma R, Augestad EH, Castelli M, Holmboe Olesen C, Clementi N, Clementi M, Mancini N, Prentoe J. Mechanisms of Hepatitis C Virus Escape from Vaccine-Relevant Neutralizing Antibodies. Vaccines (Basel) 2021;9:291. [PMID: 33804732 DOI: 10.3390/vaccines9030291] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
16 Law M. Antibody Responses in Hepatitis C Infection. Cold Spring Harb Perspect Med 2021;11:a036962. [PMID: 32341067 DOI: 10.1101/cshperspect.a036962] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
17 Gan J, Mao XR, Zheng SJ, Li JF. Invariant natural killer T cells: Not to be ignored in liver disease. J Dig Dis 2021;22:136-42. [PMID: 33421264 DOI: 10.1111/1751-2980.12968] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
18 Deng K, Xu Z, Chen M, Liu X. Keyhole Limpet Hemocyanin-Conjugated Peptides from Hepatitis C Virus Glycoproteins Elicit Neutralizing Antibodies in BALB/c Mice. J Immunol Res 2021;2021:3108157. [PMID: 33532506 DOI: 10.1155/2021/3108157] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
19 Pierce BG, Keck ZY, Wang R, Lau P, Garagusi K, Elkholy K, Toth EA, Urbanowicz RA, Guest JD, Agnihotri P, Kerzic MC, Marin A, Andrianov AK, Ball JK, Mariuzza RA, Fuerst TR, Foung SKH. Structure-Based Design of Hepatitis C Virus E2 Glycoprotein Improves Serum Binding and Cross-Neutralization. J Virol 2020;94:e00704-20. [PMID: 32878891 DOI: 10.1128/JVI.00704-20] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 4.5] [Reference Citation Analysis]
20 Mosa AI, AbouHaidar MG, Urbanowicz RA, Tavis JE, Ball JK, Feld JJ. Role of HVR1 sequence similarity in the cross-genotypic neutralization of HCV. Virol J 2020;17:140. [PMID: 32948191 DOI: 10.1186/s12985-020-01408-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
21 Muñoz-Chimeno M, Cenalmor A, Garcia-Lugo MA, Hernandez M, Rodriguez-Lazaro D, Avellon A. Proline-Rich Hypervariable Region of Hepatitis E Virus: Arranging the Disorder. Microorganisms 2020;8:E1417. [PMID: 32942608 DOI: 10.3390/microorganisms8091417] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
22 Augestad EH, Castelli M, Clementi N, Ströh LJ, Krey T, Burioni R, Mancini N, Bukh J, Prentoe J. Global and local envelope protein dynamics of hepatitis C virus determine broad antibody sensitivity. Sci Adv 2020;6:eabb5938. [PMID: 32923643 DOI: 10.1126/sciadv.abb5938] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 4.5] [Reference Citation Analysis]
23 Tong Y, Li Q, Li R, Xu Y, Pan Y, Niu J, Zhong J. A Novel Approach To Display Structural Proteins of Hepatitis C Virus Quasispecies in Patients Reveals a Key Role of E2 HVR1 in Viral Evolution. J Virol 2020;94:e00622-20. [PMID: 32554700 DOI: 10.1128/JVI.00622-20] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Qin YJ, Sha RC, Feng YC, Huang YC. Comparison of double antigen sandwich and indirect enzyme-linked immunosorbent assay for the diagnosis of hepatitis C virus antibodies. J Clin Lab Anal 2020;34:e23481. [PMID: 33245583 DOI: 10.1002/jcla.23481] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
25 Chen J, Jin L, Wang Z, Wang L, Chen Q, Cui Y, Liu G. N6-methyladenosine regulates PEDV replication and host gene expression. Virology 2020;548:59-72. [PMID: 32838947 DOI: 10.1016/j.virol.2020.06.008] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
26 Vieyres G, Reichert I, Carpentier A, Vondran FWR, Pietschmann T. The ATGL lipase cooperates with ABHD5 to mobilize lipids for hepatitis C virus assembly. PLoS Pathog. 2020;16:e1008554. [PMID: 32542055 DOI: 10.1371/journal.ppat.1008554] [Cited by in Crossref: 7] [Cited by in F6Publishing: 13] [Article Influence: 3.5] [Reference Citation Analysis]
27 Cosset FL, Mialon C, Boson B, Granier C, Denolly S. HCV Interplay with Lipoproteins: Inside or Outside the Cells? Viruses 2020;12:E434. [PMID: 32290553 DOI: 10.3390/v12040434] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
28 Stejskal L, Lees WD, Moss DS, Palor M, Bingham RJ, Shepherd AJ, Grove J. Flexibility and intrinsic disorder are conserved features of hepatitis C virus E2 glycoprotein. PLoS Comput Biol 2020;16:e1007710. [PMID: 32109245 DOI: 10.1371/journal.pcbi.1007710] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
29 Chen F, Nagy K, Chavez D, Willis S, McBride R, Giang E, Honda A, Bukh J, Ordoukhanian P, Zhu J, Frey S, Lanford R, Law M. Antibody Responses to Immunization With HCV Envelope Glycoproteins as a Baseline for B-Cell-Based Vaccine Development. Gastroenterology 2020;158:1058-1071.e6. [PMID: 31809725 DOI: 10.1053/j.gastro.2019.11.282] [Cited by in Crossref: 17] [Cited by in F6Publishing: 24] [Article Influence: 5.7] [Reference Citation Analysis]
30 Keck ZY, Pierce BG, Lau P, Lu J, Wang Y, Underwood A, Bull RA, Prentoe J, Velázquez-Moctezuma R, Walker MR, Luciani F, Guest JD, Fauvelle C, Baumert TF, Bukh J, Lloyd AR, Foung SKH. Broadly neutralizing antibodies from an individual that naturally cleared multiple hepatitis C virus infections uncover molecular determinants for E2 targeting and vaccine design. PLoS Pathog 2019;15:e1007772. [PMID: 31100098 DOI: 10.1371/journal.ppat.1007772] [Cited by in Crossref: 25] [Cited by in F6Publishing: 30] [Article Influence: 8.3] [Reference Citation Analysis]
31 Prentoe J, Velázquez-Moctezuma R, Augestad EH, Galli A, Wang R, Law M, Alter H, Bukh J. Hypervariable region 1 and N-linked glycans of hepatitis C regulate virion neutralization by modulating envelope conformations. Proc Natl Acad Sci U S A 2019;116:10039-47. [PMID: 31040211 DOI: 10.1073/pnas.1822002116] [Cited by in Crossref: 23] [Cited by in F6Publishing: 26] [Article Influence: 7.7] [Reference Citation Analysis]